PHYSICIAN OFFICE

EpiFix®

CARING FOR CHALLENGING CLOSURES WHEN PATIENTS NEED IT MOST



Protective Barrier

- Protects the wound bed to aid in the development of granulation tissue

Provides a Human Biocompatible Extracellular Matrix (ECM)

- **Structural components:** Collagen I, III, IV; elastin
- **Cell-binding domains:** Fibronectin, collagen V, VII
- **ECM-binding domains:** Proteoglycans, laminin

Retains Regulatory Proteins

- 300+ Regulatory Proteins[1-3]

- Dehydrated amnion/chorion membrane sheet allograft
- EpiFix® is SMR²T™ Technology
  Selective Membrane of Reparative and Reconstructive Tissue
- Uses Purion® patented processing

ELEVATING THE STANDARD OF CARE

EP579.001

MiMedx

EpiFix®

EpiFix is a dehydrated human amnion/chorion membrane allograft. EpiFix sheets provide a semi-permeable protective barrier that supports the healing cascade and protects the wound bed to aid in the development of granulation tissue in acute and chronic closures. EpiFix provides a biocompatible human extracellular matrix and retains 300+ regulatory proteins.[1-3]

Clinical Use Examples

- Comorbid patients with complex defects or delayed healing
- Diabetic foot ulcers (DFUs)
- Venous leg ulcers (VLUs)
- Debridements
- Decubitus ulcers

Product Advantages

- Most level I evidence in placental-based allografts: 6 EpiFix RCTs
- SMR²T Technology and patented Purion processing
- Terminally sterilized for additional level of safety
- Easy to apply
- Room temperature storage
- 5-year shelf life
- Compatible with negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBO)

Published Studies	N	Outcomes Observed in Studies
DFU RCT:[4,5] EpiFix vs. Apligraf® vs. SOC	EpiFix: 32 Apligraf: 33 SOC: 35	Complete wound closure: **85% at 4 weeks** (EpiFix vs. Apligraf *p=0.001*; EpiFix vs. SOC *p=0.001)* **95% at 6 weeks** (EpiFix vs. Apligraf *p=0.0006*; EpiFix vs. SOC *p=0.0001*) **97% at 12 weeks** (EpiFix vs. Apligraf *p=0.0001*; EpiFix vs. SOC *p=0.0001*)
VLU Multicenter RCT:[6,7] EpiFix vs. SOC	EpiFix: 52 SOC: 57	Complete wound closure (Per Protocol): **60% at 12 weeks** *(p=0.0128)* **71% at 16 weeks** *(p=0.0065)*

Physician Office* Ordering Information

Item #	Size & Description
GS-5024	24 mm disk
GS-5330	3 cm x 3 cm sheet
GS-5350	3 cm x 5 cm sheet
GS-5460	4 cm x 6 cm sheet
GS-5560	5 cm x 6 cm sheet
GS-5770	7 cm x 7 cm sheet

Item #	Size & Description
ES-3500	3 cm x 5 cm mesh sheet
ES-4400	4 cm x 4.5 cm mesh sheet
ES-5500	5 cm x 5.5 cm mesh sheet

**Q Code: 4186*

Patient Insurance Verification Team: 855.882.8480

MiMedx

SMR²T BY MIMEDX & purion BY MIMEDX

REFERENCES: 1. Koob, et al. J Biomed, Mater Res B Appl Biomater. 2014 Aug;102(6):1353-62. **2.** Lei, et al. Adv Wound Care. 2017 Feb 1;6(2):43-53. **3.** MM-RD-00086, Proteome Characterization of Purion Processed Dehydrated Human Amnion Chorion Membrane (dHACM) and Purion Plus Processed Dehydrated Human Umbilical Cord (dHUC) Allografts. **4.** Zelen, et al. Int Wound J. 2015 Dec;12(6):724-32. **5.** Zelen, et al. Int Wound J. 2016 Apr;13(2):272-82. **6.** Bianchi, et al. Int Wound J 2018 Feb;15(1):114-22. **7.** Bianchi, et al. Int Wound J. 2019 Jun;16(3)761-67.

866.477.4219 • customerservice@mimedx.com